Noah Goodman Sells 3,389 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 3,389 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider directly owned 47,179 shares in the company, valued at $5,392,087.91. This trade represents a 6.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Noah Goodman also recently made the following trade(s):

• On Thursday, June 25th, Noah Goodman sold 5,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $114.00, for a total transaction of $570,000.00.
• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.00, for a total value of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded down $0.69 during trading on Thursday, reaching $113.51. 788,284 shares of the company’s stock were exchanged, compared to its average volume of 767,552. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05. The company has a market cap of $9.34 billion, a P/E ratio of -31.80 and a beta of 1.95. The firm’s 50-day moving average price is $86.36 and its 200 day moving average price is $82.74.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.82) EPS. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares during the period. Glenmede Trust Co. NA boosted its position in Kymera Therapeutics by 3.6% during the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after buying an additional 235 shares during the period. Cetera Investment Advisers boosted its position in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after buying an additional 252 shares during the period. Larson Financial Group LLC grew its holdings in Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares during the last quarter. Finally, Swiss National Bank grew its holdings in Kymera Therapeutics by 0.3% during the 1st quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after acquiring an additional 300 shares during the last quarter.

Analysts Set New Price Targets

KYMR has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Bank of America increased their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. BTIG Research restated a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Finally, B. Riley Financial boosted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.